T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy
Clinical trial NCT07300891 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07300891
- Sponsor
- Samsung Medical Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2027-01-31
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.